Group 1 - The company, Keda Intelligent (300222.SZ), plans to issue H-shares and apply for listing on the main board of the Hong Kong Stock Exchange [1] - Currently, the company is in discussions with relevant intermediaries regarding the issuance of H-shares and the listing process [1] - Details regarding the issuance of H-shares and the listing have not yet been finalized [1]

Core Viewpoint - The company, Wanxing Technology (300624.SZ), has submitted an application for the issuance of overseas listed shares (H-shares) and for listing on the main board of the Hong Kong Stock Exchange on September 25, 2025 [1] Group 1 - The application materials were prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The submitted application documents are in draft form and may be updated and revised as necessary [1]

Core Viewpoint - The China Securities Regulatory Commission has confirmed the overseas listing applications for five companies, all of which are seeking to list in Hong Kong [1] Group 1: Company Summaries - **Lemo**: Plans to issue up to 19,166,700 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Lemo is a machine massage service provider with over 48,000 service points and more than 535,000 massage machines deployed as of July 18, 2025. Revenue for 2022 to 2024 is projected at 330 million, 587 million, and 798 million CNY, with corresponding net profits of 6.48 million, 87.34 million, and 85.81 million CNY [3][5] - **Dipu**: Plans to issue up to 115,000,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Dipu focuses on providing AI solutions, including big data analysis and enterprise-level model applications, across various sectors. Revenue for 2022 to 2024 is projected at 100 million, 129 million, and 243 million CNY, with corresponding net losses of 655 million, 503 million, and 1.255 billion CNY [5][7] - **Red Star Cold Chain**: Plans to issue up to 26,752,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Red Star Cold Chain operates a platform for frozen food trading and storage services. Revenue for 2022 to 2024 is projected at 237 million, 202 million, and 234 million CNY, with corresponding net profits of 79 million, 75 million, and 83 million CNY [7][9] - **Sailis**: Plans to issue up to 331,477,235 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Sailis is a technology-driven automotive company focused on electric vehicles, having launched several models. Revenue for 2022 to 2024 is projected at 34.1 billion, 35.8 billion, and 145.1 billion CNY, with corresponding net losses of 5.2 billion, 4.2 billion, and a net profit of 4.7 billion CNY [9][11] - **Yiteng Pharmaceutical**: Plans to achieve a listing on the Hong Kong Stock Exchange through a merger with Genor Biopharma Holdings Limited, which will issue up to 1,883,972,094 ordinary shares. Yiteng focuses on the R&D, production, and commercialization of biopharmaceutical products across various therapeutic areas. Revenue for 2022 to 2024 is projected at 2.073 billion, 2.304 billion, and 2.546 billion CNY, with corresponding net profits of 306 million, 308 million, and 388 million CNY [11]

Core Points - Company has received a notification from the China Securities Regulatory Commission regarding the overseas issuance and listing, marking significant progress in its efforts to go public abroad [2] - The company plans to issue up to 331,477,235 overseas listed ordinary shares (H-shares) and list them on the Hong Kong Stock Exchange [2] - The company must report any major events to the China Securities Regulatory Commission during the overseas listing process and must also report the issuance and listing status within 15 working days after completion [2] Production and Sales Data - In August, the company's total automobile production reached 47,097 units, representing a year-on-year increase of 14.24% [2] - The cumulative total production for the year stands at 296,202 units, showing a year-on-year decrease of 9.21% [2] - The total automobile sales in August were 45,818 units, reflecting a year-on-year increase of 8.43% [2] - The cumulative total sales for the year are 292,364 units, indicating a year-on-year decline of 10% [2]

中国经济网北京9月25日讯 富瀚微（300613.SZ）昨日发布关于控股股东、实际控制人及其一致行 动人持股比例变动触及1%整数倍的公告。 本次权益变动系因富瀚微股东杰智控股有限公司（以下简称"杰智控股"）减持股份及公司总股本增 加，导致公司控股股东、实际控制人杨小奇先生及其一致行动人杰智控股有限公司、陈春梅女士、龚传 军先生合计持股比例累计变动触及1%整数倍。本次权益变动不触及要约收购，不会导致公司控股股东 及实际控制人发生变化，不会影响公司的治理结构和持续经营。 富瀚微8月28日披露了关于公司筹划境外发行股份（H股）并在香港联合交易所有限公司上市的提 示性公告。 为深化公司全球化战略布局，加快海外业务发展，提升公司国际化品牌形象，同时打造多元化资本 运作平台，进一步增强公司资本实力，助力公司高质量发展，公司拟筹划境外发行股份（H股）并申请 在香港联交所挂牌上市（以下简称"本次发行H股并上市"）的相关工作，正在计划与相关中介机构就本 次发行H股并上市的具体推进工作进行商讨，关于本次发行H股并上市的细节尚未确定。 待确定具体方案后，本次发行H股并上市尚需提交公司董事会和股东会审议，并需取得中国证券监 督管理委 ...

Core Viewpoint - The company, Shanjin International Gold Co., Ltd., has submitted an application for the issuance of overseas listed shares (H-shares) and listing on the Hong Kong Stock Exchange on September 24, 2025, which is a significant step towards expanding its capital base and attracting foreign investment [1][2]. Group 1 - The application for the H-share issuance has been filed with the Hong Kong Stock Exchange and is in compliance with the requirements set by the Hong Kong Securities and Futures Commission [1]. - The subscription for this issuance is limited to qualified overseas investors and domestic qualified investors who are authorized to conduct overseas securities investments under Chinese laws [1]. - The company will not publish the application materials on domestic stock exchange websites or media, but provides links for domestic investors to access the information on the Hong Kong Stock Exchange website [1]. Group 2 - The issuance is subject to approval and/or registration by relevant government and regulatory bodies, including the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating a level of uncertainty regarding the approval process [2]. - The company commits to timely information disclosure in accordance with relevant laws and regulations based on the progress of the issuance [2].

Group 1 - Company plans to issue H-shares and list on the Hong Kong Stock Exchange to optimize overseas business layout and diversify financing channels [1] - The H-share issuance is subject to approval from the board, shareholders, and regulatory bodies, with significant uncertainty regarding its implementation [1] - For the first half of 2025, the company reported revenue of approximately 8.494 billion yuan, a year-on-year increase of about 56.59%, and a net profit of approximately 1.683 billion yuan, up about 47.50% [1] Group 2 - The PCB business generated revenue of approximately 8.152 billion yuan, reflecting a year-on-year growth of about 57.20%, although the gross margin decreased by approximately 1.49 percentage points due to increased equity incentive costs and losses from the Thailand plant [1] - Senior management member Li Minggui plans to reduce his shareholding by up to 160,400 shares, representing about 0.0083% of the total share capital, within a three-month period starting from September 23, 2025 [2] - The company reported a negative cash flow from investment activities of approximately 1.363 billion yuan for the first half of 2025, a decline of 31.85% compared to the same period last year [3] Group 3 - Negative cash flow from investment activities for 2023 and 2024 was reported at approximately 1.870 billion yuan and 3.035 billion yuan, respectively [4]

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase its global visibility, and optimize its capital structure [1][2]. Group 1 - The company is currently discussing the details of the H-share listing with relevant intermediaries, and specific details have not yet been finalized [2]. - The H-share listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, the Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]. - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations as the H-share listing progresses [2].

Core Points - Company is planning to issue H shares and list on the Hong Kong Stock Exchange to enhance international strategy and brand recognition [1][2] - The details of the H share issuance and listing are still under discussion with relevant intermediaries [1] - The issuance and listing require approval from the board, shareholders, and regulatory bodies, which introduces significant uncertainty [2] Group 1 - Company aims to boost international competitiveness through H share issuance [1] - Discussions with intermediaries regarding the H share listing are ongoing [1] - Approval from various regulatory bodies is necessary for the H share issuance to proceed [2]

Group 1 - The core point of the news is that Nanhua Futures Co., Ltd. plans to issue up to approximately 155 million shares for overseas listing on the Hong Kong Stock Exchange, as per the notice from the China Securities Regulatory Commission [1][2] - Nanhua Futures was established in 1996 and is a comprehensive global financial services platform, providing services including domestic futures brokerage, risk management, wealth management, and overseas financial services [2] - As of September 22, 2025, Nanhua Futures has a total market capitalization of approximately RMB 13.1 billion [1] Group 2 - According to a report by Frost & Sullivan, Nanhua Futures ranks 8th among all futures companies in China by total revenue in 2023, and 1st among non-financial institution-related futures companies [2] - In terms of futures brokerage commission income for 2023, Nanhua Futures ranks 12th among all futures companies and 1st among non-financial institution-related futures companies [2] - Nanhua Futures ranks 1st among all futures companies in China by overseas income and 2nd in return on equity (ROE) among all 53 listed securities and futures companies in China for the first nine months of 2024 [2]